Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Oct-23 4:48 PM View:  | Daniels Eric Joseph Chief Development Officer | Kiora Pharmaceuticals Inc (EYEG) | 29-Sep-23 | Grant | 62,500 | -- | -- | 242% 25.84K to 88.34K | |
| 03-Oct-23 4:49 PM View: | Tosca Melissa EVP Finance | Kiora Pharmaceuticals Inc (EYEG) | 29-Sep-23 | Grant | 30,000 | -- | -- | 612% 4.9K to 34.9K | |
| 03-Oct-23 4:47 PM View: | Strem Brian M. President and CEO Director | Kiora Pharmaceuticals Inc (EYEG) | 29-Sep-23 | Grant | 75,000 | -- | -- | 261% 28.78K to 103.78K | |
| 07-Mar-23 8:14 PM View: | Daniels Eric Joseph Chief Development Officer | Kiora Pharmaceuticals Inc (EYEG) | 03-Mar-23 | Grant | 15,600 | -- | -- | 152% 10.24K to 25.84K | |
| 07-Mar-23 8:15 PM View: | Tosca Melissa EVP Finance | Kiora Pharmaceuticals Inc (EYEG) | 03-Mar-23 | Grant | 2,400 | -- | -- | 48% 5.0K to 7.4K | |
| 07-Mar-23 8:15 PM View: | Strem Brian M. President and CEO Director | Kiora Pharmaceuticals Inc (EYEG) | 03-Mar-23 | Grant | 15,600 | $3.83 | $59,748.00 | 118% 13.18K to 28.78K | |
| 25-Oct-22 5:34 PM View: | Daniels Eric Joseph Chief Development Officer | Kiora Pharmaceuticals Inc (EYEG) | 21-Oct-22 | Grant | 10,000 | -- | -- | 4202% 0.24K to 10.24K | |
| 25-Oct-22 5:32 PM View: | Tosca Melissa EVP of Finance | Kiora Pharmaceuticals Inc (EYEG) | 21-Oct-22 | Grant | 2,500 | -- | -- | 100% 0 to 2.5K | |
| 25-Oct-22 5:30 PM View: | Strem Brian M. President and CEO Director | Kiora Pharmaceuticals Inc (EYEG) | 21-Oct-22 | Grant | 12,500 | -- | -- | 1830% 0.68K to 13.18K | |
| 11-Feb-22 10:00 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 10-Feb-22 | Payment of Exercise | 108 | $0.69 | $74.52 | (< 1%) 22.85K to 22.75K | |
| 06-Jan-22 5:10 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 05-Jan-22 | Payment of Exercise | 114 | $1.08 | $123.12 | (< 1%) 22.97K to 22.85K | |
| 06-Jan-22 5:10 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 05-Jan-22 | Payment of Exercise | 326 | $1.08 | $352.08 | (< 1%) 68.02K to 67.69K | |
| 08-Dec-21 4:16 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 07-Dec-21 | Payment of Exercise | 273 | $1.30 | $354.90 | (< 1%) 68.29K to 68.02K | |
| 08-Dec-21 4:15 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 07-Dec-21 | Payment of Exercise | 91 | $1.30 | $118.30 | (< 1%) 23.06K to 22.97K | |
| 22-Nov-21 4:35 PM View: | Strem Brian M. President and CEO Director | Kiora Pharmaceuticals Inc (EYEG) | 18-Nov-21 | Private Purchase | 17,853 | $1.41 | $25,172.70 | 188% 9.52K to 27.37K | |
| 03-Nov-21 4:16 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 02-Nov-21 | Payment of Exercise | 62 | $1.98 | $122.76 | (< 1%) 15.2K to 15.14K | (< 1%) |
| 03-Nov-21 4:15 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 02-Nov-21 | Payment of Exercise | 83 | $1.98 | $164.34 | (< 1%) 23.14K to 23.06K | (< 1%) |
| 03-Nov-21 4:16 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 02-Nov-21 | Payment of Exercise | 250 | $1.98 | $495.00 | (< 1%) 68.54K to 68.29K | (< 1%) |
| 22-Nov-21 4:35 PM View: | Strem Brian M. President and CEO Director | Kiora Pharmaceuticals Inc (EYEG) | 21-Oct-21 | Grant | 9,517 | -- | -- | 100% 0 to 9.52K | |
| 05-Oct-21 6:40 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 04-Oct-21 | Payment of Exercise | 83 | $2.01 | $166.83 | (< 1%) 23.23K to 23.14K | 1% |
| 05-Oct-21 6:39 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 04-Oct-21 | Payment of Exercise | 249 | $2.01 | $500.49 | (< 1%) 68.79K to 68.54K | 1% |
| 05-Oct-21 6:40 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 04-Oct-21 | Payment of Exercise | 62 | $2.01 | $124.62 | (< 1%) 15.26K to 15.2K | 1% |
| 03-Sep-21 4:17 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 02-Sep-21 | Payment of Exercise | 253 | $1.81 | $457.93 | (< 1%) 69.04K to 68.79K | (9%) |
| 03-Sep-21 4:15 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 02-Sep-21 | Payment of Exercise | 61 | $1.81 | $110.41 | (< 1%) 15.32K to 15.26K | (9%) |
| 03-Sep-21 4:16 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 02-Sep-21 | Payment of Exercise | 84 | $1.81 | $152.04 | (< 1%) 23.31K to 23.23K | (9%) |
| 04-Aug-21 5:46 PM View: | Manzo Michael P. VP of Engineering | Kiora Pharmaceuticals Inc (EYEG) | 03-Aug-21 | Payment of Exercise | 65 | $2.40 | $156.00 | (< 1%) 15.44K to 15.38K | 18% |
| 04-Aug-21 5:45 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 03-Aug-21 | Payment of Exercise | 63 | $2.40 | $151.20 | (< 1%) 15.38K to 15.32K | 18% |
| 04-Aug-21 5:45 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 03-Aug-21 | Payment of Exercise | 87 | $2.40 | $208.80 | (< 1%) 23.4K to 23.31K | 18% |
| 04-Aug-21 5:46 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 03-Aug-21 | Payment of Exercise | 261 | $2.40 | $626.40 | (< 1%) 69.31K to 69.04K | 18% |
| 03-Aug-21 10:00 PM View: | Armistice Capital, LLC 10% Owner | Kiora Pharmaceuticals Inc (EYEG) | 02-Aug-21 | Market Sale | 192,775 | $2.40 | $463,046.00 | (20%) 977.77K to 785.0K | 18% |
| 03-Aug-21 10:00 PM View: | Armistice Capital, LLC 10% Owner | Kiora Pharmaceuticals Inc (EYEG) | 30-Jul-21 | Market Sale | 68,188 | $2.69 | $183,562.00 | (7%) 1.05M to 977.77K | 27% |
| 29-Jul-21 7:59 PM View: | Armistice Capital, LLC Director 10% Owner | Kiora Pharmaceuticals Inc (EYEG) | 29-Jul-21 | Market Sale | 400,000 | $3.00 | $1,200,000.00 | (28%) 1.45M to 1.05M | 34% |
| 29-Jul-21 7:59 PM View: | Armistice Capital, LLC Director 10% Owner | Kiora Pharmaceuticals Inc (EYEG) | 28-Jul-21 | Market Sale | 375,443 | $3.28 | $1,232,620.00 | (21%) 1.82M to 1.45M | 40% |
| 29-Jul-21 7:59 PM View: | Armistice Capital, LLC Director 10% Owner | Kiora Pharmaceuticals Inc (EYEG) | 27-Jul-21 | Conversion | 852,500 | $4.80 | $4,092,000.00 | 25% 3.35M to 4.2M | (59%) |
| 29-Jul-21 7:59 PM View: | Armistice Capital, LLC Director 10% Owner | Kiora Pharmaceuticals Inc (EYEG) | 27-Jul-21 | Market Sale | 2,377,700 | $5.09 | $12,113,600.00 | (57%) 4.2M to 1.82M | 61% |
| 06-Jul-21 10:00 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 02-Jul-21 | Payment of Exercise | 180 | $3.70 | $666.00 | (< 1%) 23.58K to 23.4K | 47% |
| 06-Jul-21 10:00 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 02-Jul-21 | Payment of Exercise | 877 | $3.70 | $3,244.90 | (1%) 70.18K to 69.31K | 47% |
| 06-Jul-21 10:00 PM View: | Manzo Michael P. VP of Engineering | Kiora Pharmaceuticals Inc (EYEG) | 02-Jul-21 | Payment of Exercise | 160 | $3.70 | $592.00 | (1%) 15.6K to 15.44K | 47% |
| 07-Jun-21 5:02 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 04-Jun-21 | Payment of Exercise | 878 | $4.19 | $3,678.82 | (1%) 71.06K to 70.18K | 53% |
| 07-Jun-21 5:01 PM View: | Manzo Michael P. VP of Engineering | Kiora Pharmaceuticals Inc (EYEG) | 04-Jun-21 | Payment of Exercise | 155 | $4.19 | $649.45 | (< 1%) 15.76K to 15.6K | 53% |
| 07-Jun-21 5:02 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 04-Jun-21 | Payment of Exercise | 180 | $4.19 | $754.20 | (< 1%) 23.76K to 23.58K | 53% |
| 07-Jun-21 5:01 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 04-Jun-21 | Payment of Exercise | 155 | $4.19 | $649.45 | (< 1%) 15.69K to 15.54K | 53% |
| 05-May-21 9:57 PM View: | Manzo Michael P. VP of Engineering | Kiora Pharmaceuticals Inc (EYEG) | 04-May-21 | Payment of Exercise | 158 | $4.13 | $652.54 | (< 1%) 15.92K to 15.76K | 52% |
| 05-May-21 9:57 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 04-May-21 | Payment of Exercise | 177 | $4.13 | $731.01 | (< 1%) 23.93K to 23.76K | 52% |
| 05-May-21 9:56 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 04-May-21 | Payment of Exercise | 191 | $4.13 | $788.83 | (1%) 15.88K to 15.69K | 52% |
| 05-May-21 9:57 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 04-May-21 | Payment of Exercise | 889 | $4.13 | $3,671.57 | (1%) 71.95K to 71.06K | 52% |
| 09-Apr-21 4:16 PM View: | Romano Sarah Chief Financial Officer | Kiora Pharmaceuticals Inc (EYEG) | 08-Apr-21 | Payment of Exercise | 180 | $4.94 | $889.20 | (< 1%) 24.11K to 23.93K | 60% |
| 09-Apr-21 4:15 PM View: | Mann Brenda VP of Research & Development | Kiora Pharmaceuticals Inc (EYEG) | 08-Apr-21 | Payment of Exercise | 192 | $4.94 | $948.48 | (1%) 16.08K to 15.88K | 60% |
| 09-Apr-21 4:16 PM View: | From Stephen Executive Chairman Director | Kiora Pharmaceuticals Inc (EYEG) | 08-Apr-21 | Payment of Exercise | 899 | $4.94 | $4,441.06 | (1%) 72.85K to 71.95K | 60% |
| 09-Apr-21 4:16 PM View: | Manzo Michael P. VP of Engineering | Kiora Pharmaceuticals Inc (EYEG) | 08-Apr-21 | Payment of Exercise | 194 | $4.94 | $958.36 | (1%) 16.11K to 15.92K | 60% |
